The recall of Panadol Baby and Infant Suspension by GlaxoSmithKline (GSK) weeks ago has triggered an alarm. Medical practitioners have warned that prolonged use of wrong dosage of syrups could have serious health implications. The Pharmaceutical Society of Kenya (PSK) President, Dr Paul Mwaniki, raised the red flag last month and revealed that the recalled drug was still in the market, despite complaints raised on dosage and calibrations of syringes packed for its administration.
Dr Mwaniki said that though there were no major issues with the Panadol suspension, the wrong dosage was subjecting babies to high levels of paracetamol that could cause liver complications in the long-term.